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Abstract
AIM
To identify short-term and oncologic outcomes of 
pelvic exenterations (PE) for locally advanced primary 
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rectal cancer (LAPRC) in patients included in a national 
prospective database.
METHODS
Few studies report on PE in patients with LAPRC. 
For this study, we included PE for LAPRC performed 
between 2006 and 2017, as available, from the 
Rectal Cancer Registry of the Spanish Association of 
Surgeons [Asociación Española de Cirujanos (AEC)]. 
Primary endpoints included procedure-associated 
complications, 5-year local recurrence (LR), disease-free 
survival (DFS) and overall survival (OS). A propensity-
matched comparison with patients who underwent 
non-exenterative surgery for low rectal cancers was 
performed as a secondary endpoint.
 
RESULTS
Eight-two patients were included. The mean age was 61.8 
± 11.5 years. More than half of the patients experienced 
at least one complication. Surgical site infections were the 
most common complication (abdominal wound 18.3%, 
perineal closure 19.4%). Thirty-three multivisceral 
resections were performed, including two hepatectomies 
and four metastasectomies. The long-term outcomes of 
the 64 patients operated on before 2013 were assessed. 
The five-year LR was 15.6%, the distant recurrence rate 
was 21.9%, and OS was 67.2%, with a mean survival of 
43.8 mo. R+ve resection increased LR [hazard ratio (HR) 
= 5.58, 95%CI: 1.04-30.07, P  = 0.04]. The quality of 
the mesorectum was associated with DFS. Perioperative 
complications were independent predictors of shorter 
survival (HR = 3.53, 95%CI: 1.12-10.94, P  = 0.03). In 
the propensity-matched analysis, PE was associated with 
better quality of the specimen and tended to achieve 
lower LR with similar OS.
CONCLUSION
PE is an extensive procedure, justified if disease-free 
margins can be obtained. Further studies should define 
indications, accreditation policy, and quality of life in 
LAPRC.
Key words: Pelvic exenteration; Advanced rectal cancer; 
Colorectal surgery; Complication; Outcome
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Pelvic exenteration (PE) for locally advanced 
primary rectal cancer (LAPRC) is associated with high 
rates of perioperative adverse events, but the survival 
benefit obtained when R-ve margins are achieved 
outweighs this risk. In low LAPRC, PE achieved better 
pathologic outcomes, resulting in a trend towards 
reduced LR compared with non-exenterative procedures.
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INTRODUCTION
Colorectal cancer is the fourth cause of cancer-related 
death in United States[1]. A recent analysis of the SEER 
programme concerning age-specific annual percent 
change in incidence rates from 2000 to 2013 showed 
that the incidence of rectal cancer and advanced 
disease has slightly decreased, but it is less than that 
of colon cancer[2]. Five-year survival is influenced by 
tumour stage, ranging from 90% in cancer confined 
to the primary site and 71% in those with local node 
involvement to 14% in Stage IV[3]. One-third of newly 
diagnosed rectal cancers in the United Kingdom will be 
locally advanced at the time of diagnosis, accounting for 
more than 4600 cases of cancer per year[4,5].
Recent advances in the multimodal management 
of patients with rectal cancer invading local structures 
have led to an increase in the rate of patients amenable 
to receive surgery along the anatomical planes after 
neoadjuvant treatment. Nevertheless, a relatively high 
number of patients might still be found with tumours 
invading surrounding organs[4]. 
Pelvic exenteration (PE) is a technically demanding 
procedure involving “en-bloc” excision of the rectum and 
adjacent invaded organs, aiming at obtaining disease-
free resection margins. Over time, contraindications 
to such a demolitive approach have been gradually 
reduced as a result of perioperative patient conditioning, 
increased surgical experience, and postoperative multidi-
sciplinary management[5-7]. Surgery beyond the total 
mesorectal excision (TME) plane and involving sacrifice 
of other pelvic organs for locally recurrent or advanced 
rectal cancer has been analogous to a “sarcoma-like” 
procedure[6,8-10], during which several surgical teams 
and specialties need to be involved. PE for rectal cancer 
brings higher risks of complications, ranging from 25% 
to 42%[5,8,11], with studies reporting higher rates when 
PE for other-than-rectal cancers is included[12]. The 
high incidence of complications is downplayed by the 
survival benefits obtained by excision of the pelvic mass 
with microscopically negative margins (R0)[7,8,12-14]. Few 
studies have focused on the outcomes of PE in locally 
advanced primary rectal cancer (LAPRC), although 
an increasing number of patients are being offered 
this extensive procedure. A recent study of the PelvEx 
Collaborative found that the median life expectancy after 
curative PE for LAPRC surpasses 40 mo, but median 
survival after resections with macroscopically involved 
margins drops to less than one year[14]. 
As part of a national quality improvement programme 
in the treatment of rectal cancer, the Spanish Association 
of Surgeons [“Asociación Española de Cirujanos” (AEC)] 
started an online database[15] in which all primary rectal 
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cancers were prospectively included on a voluntary basis. 
Data on patients undergoing PE were also recoded.
The aims of this study are to assess the short- and 
long-term outcomes of PE for primary LAPRC in patients 
included in the AEC registry and to compare the oncologic 
results of PE with a matched group of patients treated 
with non-exenterative TME during the study timeframe.
MATERIALS AND METHODS
This study complies with the STROBE statement for 
observational studies[16] (Flowchart in Supplementary 
Figure 1; checklist available as uploaded STROBE 
Statement). In 2006, the AEC established a national 
audit project to improve the outcomes of rectal cancer 
surgery. The project was named “Viking” because it was 
inspired by the project from Norway[17] and followed 
the same principles[18]. Between 2006 and 2017, 105 
Spanish hospitals joined the online registry, with over 
18000 patients included. The aim of this study was to 
assess morbidity and long-term outcomes of PE for 
LAPRC.
Inclusion and exclusion criteria
We included patients who underwent PE for LAPRC 
between 2006 and 2017. The patients were only 
included if they underwent surgery with curative intent. 
For the survival analysis, only patients with a minimum 
follow up of 5 years were evaluated. 
The patients who were unfit for surgery, those who 
underwent palliative surgery, those diagnosed with 
other malignancies besides colonic malignancies, and 
those with unsatisfactory information were excluded 
from the analysis.
Endpoints and definitions
The primary aims of this study were: (1) short-term 
morbidity and mortality of PE for LAPRC; (2) overall 
5-year local recurrence (LR), disease-free survival (DFS), 
and overall survival (OS). Secondary outcomes included 
oncologic outcomes after PE compared with patients in 
the registry who underwent TME for distal rectal cancer 
surgery during the same timeframe, with a propensity-
matched analysis.
The online database allows the investigators to 
classify the type of intervention performed. Only “PE” 
interventions were included in the analysis and consisted 
of either posterior (removal of rectum, internal genital 
organs in female) or total (removal of rectum and 
bladder, in male and female). Indications for surgery and 
perioperative management were not standardized before 
starting the study, although most centres followed the 
agreed-upon criteria[19]. 
Thirty-day complications were collected, and the 
responsible collaborator at each centre updated the 
data on oncologic outcome yearly[18,20]. 
Specimen assessment and reporting have been 
previously described[18,20,21]. Briefly, margins were 
considered tumour-free if no microscopic involvement 
was seen at pathology. The circumferential resection 
margin was considered involved if cancer cells were 
found 1 mm or less from the margin[20]. The quality of 
the mesorectum and abdominoperineal excision was 
scored using three grades as described by others[20-23]. 
LR was defined as a mass near or at the same place 
as the original tumour, after a period of time in which 
the tumour was not detected. LR was included only if 
an imaging exam proved the recurrence combined with 
raised CEA.
DFS was defined as time to develop a distant 
disease relapse that was not present or suspected at 
primary surgery. Distant metastases included para-
aortic and inguinal nodes.
OS was defined as time to death for any reason.
Detailed definitions and scope of the registry have been 
previously reported[15,18,20] (http://www.aecirujanos.es/
images/stories/recursos/secciones/coloproctologia/2015/
proyecto_vikingo/documentos/definiciones_proyecto_viki
ngo.pdf).
For the secondary aims, the group that was pro-
pensity matched with PE included all patients from the 
database with low rectal cancer who underwent TME 
surgery with abdominoperineal excision, extralevator 
abdominoperineal excision, and low anterior resection 
between March 2006 and December 2013.
Statistical analysis
Continuous variables are reported as the means ± 
standard deviations (SD), and categorical variables are 
reported as the numbers with percentages (%). 
For the secondary aims, the propensity-matched 
analysis for complications was carried out based on the 
following variables: American Society of Anesthesiologists’ 
(ASA) score, neoadjuvant treatment, and pT stage. Only 
patients with cancer of the lower third of the rectum (0-6 
cm from anal verge) who underwent curative TME surgery 
were included.
Categorical variables were compared with Fisher’s 
exact test and Chi square test as appropriate, whereas 
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Figure 1  Overall local recurrence after pelvic exenteration for locally 
advanced primary rectal cancer. 
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hospital of 2.5 ± 3.1 overall. 
Baseline patient characteristics and surgical details 
Demographics and perioperative features are sum-
marized in Table 1. The mean age of the patients was 
61.8 ± 11.5 years, 65.9% were men, 34.1% were 
women, and 45.1% were classified as ASA ≥ III. Most 
patients were staged as MRcT4 [T4 with magnetic 
resonance (MR)] and had extensive nodal involvement. 
The tumour was located in the proximal third of the 
rectum (15-11 cm) in 18 (22%) patients, in the middle 
third (10-7 cm) in 31 (37.8%) patients, and in the distal 
third (6-0 cm) in 33 (40.2%) patients. Seven patients 
underwent PE with concomitant distant metastases. 
Neoadjuvant treatment was offered to 72% of patients 
and included radiotherapy in 93% of them. No data were 
available concerning time to surgery after treatment. 
Fifty-four (65.9%) patients received postoperative 
chemotherapy, which was associated with radiotherapy 
in 6 (11.1%). An anastomosis was attempted in 15 
patients. In the latter group, eight patients received 
preoperative radiotherapy and postoperative treatment 
was given in nine, including radiotherapy in two.
Thirty-three multivisceral resections were performed, 
including two hepatectomies and four metastasectomies. 
One liver lesion was treated with radiofrequency ablation. 
One patient received peritonectomy.
Primary aim: Short-term outcomes and pathology
Perioperative death rates did not exceed 2.5%. More 
than half of the patients experienced at least one 
complication, and 10% required reoperation. Intra-
abdominal septic complications occurred in 10% of the 
patients.
Surgical site infections affected the abdominal 
wound in 18.3% and the perineal closure in 19.4% of 
those who did not receive an anastomosis. Short-term 
outcomes are reported Table 2.
Table 3 depicts pathological outcomes. Most cancers 
were pT4b (36.6%), with significant reduction of cN2 
rate in favour of pN0 (40.2%) and pN1 (20.7%). The 
mean number of isolated nodes was well over 12 and 
rarely harboured cancer (in 25.6%). Nineteen patients 
(23.2%) received R+ve resection - one with both 
circumferential and distal margins affected.  
Twenty percent of patients did not have any 
response to preoperative neoadjuvant treatment, one 
patient had complete pathological response (1.7%), 
and the remaining patients had a different spectrum 
of response (detailed in Table 3). The quality of 
mesorectum was classified as “good” (complete)[20-23] in 
74.4% of patients.
Primary aim: Recurrence and survival 
For the purpose of long-term outcomes, we excluded 18 
patients who received PE after 2013, thereby analysing 
64 patients.
The five-year LR was 15.6%, the distant recurrence 
continuous variables were compared with Mann-Whitney 
U test.
Kaplan-Meier survival curves were generated to 
assess 5-year survival, and log rank test was used for 
comparisons when applicable. Cox regression analysis 
was used to identify predictors of LR, DFS, and OS, 
including the following variables: resection margin 
status, quality of mesorectum, neoadjuvant treatment, 
adjuvant treatment, and perioperative complications. 
The results are reported as hazard ratio (HR) with 95% 
confidence intervals (95%CI). HR > 1 is associated with 
increased risk. Patients lost at follow up were classified 
as censored.
P values < 0.05 were considered statistically significant. 
The Statistical Package for Social Sciences (SPSS version 
24.0.0; IBM SPSS statistics, IBM Corporation, Armonk, 
NY) was used for the descriptive analyses. 
RESULTS
We analysed data on 82 patients undergoing PE for LAPRC 
in 33 hospitals, with a mean number of procedures per 
Table 1  Demographic, preoperative, and surgical details for 
82 pelvic exenterations n  (%)
Variable Value
Age, yr 61.8 (11.5)
Gender
   Male 54 (65.9)
   Female 28 (34.1)
ASA score
   I 3 (3.7)
   II 42 (51.2)
   III 33 (40.2)
   IV 4 (4.9)
Obstruction 5 (6.1)
MR T
   T3 13 (15.9)
   T4 56 (68.3)
   Missing 13 (15.9)
MR N
   N0 11 (13.4)
   N1 24 (29.3)
   N2 35 (42.7)
   Missing 12 (14.6)
Sphincters involved 22 (26.8)
Metastasis at presentation 7 (8.5)
Neoadjuvant treatment 59 (72)
   Long course RT 3 (5)
   Long course CRT 41 (69.5)
   CxT 4 (6.8)
   Short Course RT 4 (6.8)
   CxT followed by RT 7 (11.9)
Adjuvant treatment 54 (65.9)
   CRT 6 (11.1)
   CT 48 (88.9)
Perioperative transfusions, n 3.4 (2)
Anastomosis 15 (18.3)
Synchronous metastasis resected 4 (6.8)
Data are expressed as number of patients (%) or median (25-75 percentiles). 
ASA: American Society of Anaesthesiologists; CRT: Chemoradiation 
therapy; CxT: Chemotherapy; MR: Magnetic resonance; RT: Radiotherapy.
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rate was 21.9%, and OS was 67.2%, with a mean 
survival of 43.8 mo (Figures 1-3). Oncologic outcomes 
tended to be worse in pN+ patients in all dimensions, 
although these differences did not reach statistical 
significance.
The Cox regression analysis identified R+ve resection 
to increase the risk of LR (HR = 5.58, 95%CI: 1.04-30.07, 
P = 0.04), and partially good or bad quality mesorectum 
to predict shorter DFS (HR = 4.37, 95%CI: 1.02-18.65, 
P = 0.04, and HR = 6.29, 95%CI: 1.2-32.94, P = 
0.03, respectively). Perioperative complications were 
independent predictors of shorter survival (HR = 3.53, 
95%CI: 1.12-10.94, P = 0.03).
Secondary aims: Propensity-matched sub-analyses in 
lower rectum
The propensity match analysis identified 51 patients 
who received either PE (n = 26) or non exenterative 
TME (n = 25) for primary adenocarcinoma of the 
lower rectum. Patient characteristics are summarized 
in Table 4. TME patients more frequently received an 
anastomosis (3.8% vs 80%, PE vs TME, P < 0.001) 
and were less likely to need transfusions (P = 0.035). 
PE was associated with better quality of the specimen, 
consisting of fewer R+ve resections and higher rates of 
good quality mesorectum.
LR tended to be lower in patients who received PE 
compared with TME (P = 0.34) (Supplementary Figure 
2), with comparable OS (P = 0.96) (Supplementary 
Figure 3). 
DISCUSSION
The present study showed good survival following PE 
for LAPRC in a cohort of patients included in a national 
prospective database. The procedure brings a significant 
risk of complications, occurring in 50% of patients, and 
non-negligible perioperative death rates. Pathological 
outcomes and long-term survival justify such extensive 
operations. Negative resection margins were achieved 
in 76.8% of patients and were associated with reduced 
rates of LR. Complications impaired 5-year survival. 
Comparing patients who underwent PE vs TME for 
low rectal cancer, PE showed a trend towards better 
specimen quality and lower rates of R+ve resection and 
tended to have longer LR-free intervals.
Since the first description of PE for gynaecologic 
cancer in 1948[6,24], the procedure has been adopted 
with increasing success rates in patients with rectal 
cancer[8,12-14,25-27]. The PE of colorectal interest involves 
“en bloc” resection of the cancer and of the surrounding 
structures/organs, namely, the rectum, distal colon, 
internal reproductive organs, draining lymph in posterior 
PE (also known as composite resections) or bladder, lower 
ureters, rectum, distal colon, sacrum, reproductive organs, 
draining lymph nodes and peritoneum in total PE[6,28].
Perioperative complications in our study were in 
line with rates reported in the literature. A systematic 
review[29] with 23 studies found that postoperative 
complications ranged between 37% and 100% (median 
57%) and that perioperative mortality ranged between 
0% and 25% (median 2.2%) after PE for LAPRC and 
recurrent cancer. The studies including all types of 
pelvic malignancies reported a complication rate as 
Table 2  Short-term outcomes n  (%)
Variable Value
Complications, any 45 (54.9)
Reoperation 8 (9.8)
Perioperative death 2 (2.4)
Sepsis 4 (4.9)
Abdominal Surgical Site Infection 15 (18.3)
Abdominal hernia 2 (2.4)
Perineal Wound Complications 13/67 (19.4)
Intra-abdominal septic complications 8 (9.8)
Injury to hollow viscera 2 (2.4)
Ileus 9 (11)
Urinary tract complications 9 (11)
Pulmonary complications 8 (9.8)
Neurological complications 2 (2.4)
Multiorgan failure 2 (2.4)
CVC infection 2 (2.4)
Acute kidney failure 2 (2.4)
Data are expressed as number of patients (%) or median (25-75 
percentiles). CVC: Central venous catheter.
Table 3  Pathological outcomes and survival n  (%)
Variable Value
pT
   Tx 2 (2.4)
   T0 1 (1.2)
   T2 2 (2.4)
   T3a,b 6 (7.3)
   T3c,d 13 (15.9)
   T4a 27 (32.9)
   T4b 30 (36.6)
   Missing 1 (1.2)
pN
   Nx 25 (30.5)
   N0 33 (40.2)
   N1 17 (20.7)
   N2 6 (7.3)
   Missing 1 (1.2)
Nodes isolated 15.5 (10.6)
Positive nodes 1.1 (0.4)
Resection margins involved 19 (23.2)
Response to neoadjuvant treatment (n = 59)
   Complete 1 (1.7)
   Islands of tumour cells 1 (1.7)
   Predominantly fibrotic 20 (33.9)
   Predominantly tumour nests 21 (35.6)
   No response 12 (20.3)
   Missing 4 (6.8)
Quality of mesorectum[20-23]
   Good/complete 61 (74.4)
   Partially good/near complete 9 (11)
   Bad/incomplete 8 (9.8)
   Missing 4 (4.9)
Data are expressed as number of patients (%) or median (25-75 
percentiles).
Pellino G et al . PE for LAPRC
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high as 64%[6]. In more recent series, complications 
occurred in 27.7% to 42.2% of patients who underwent 
PE for LAPRC[5,11,13,26]. Irrespective of ASA score, the 
rate of patients developing serious complications 
might be similar to that observed after TME anterior 
resection[11,30]. In our series, the rate of patients who 
developed complications needing reintervention was 
10%. Surgeons willing to set up units dedicated to PE 
need to be prepared to long postoperative stays and 
significant morbidity, even in experienced hands[19]; 
early diagnosis and proactive management will be 
important to reduce their effects. Hsu et al[31] have 
discarded any influence of perioperative complications 
on survival after LAPRC surgery, but in our series, 
complications were independently associated with 
shorter life expectancy (HR = 3.53, 95%CI: 1.12-10.94, 
P = 0.03). These findings need to be carefully evaluated 
in the context of surgeon-specific outcomes[32] and 
learning curves associated with PE[33], and any attempt 
should be made to reduce complications, e.g., being 
very selective in performing anastomosis and including 
a dedicated anaesthetist in the multidisciplinary team to 
allow for patient optimization[5,19,30].
The rate of R+ve resection in our study was similar 
to other reports but likely improvable. Combined with 
the quality of the excised specimen, it represents a 
reliable surrogate marker for LR and survival after 
PE[6,7,8,25]. The number of lymph nodes harvested in 
Table 4  Propensity-matched analysis n  (%)
Pelvic exenteration n  = 26 Non-exenterative total mesorectal excision 
n  = 25
P value
Male 18 (58.1) 13 (52) 0.208
Age at surgery 63.1 ± 8.6 62.3 ± 13.7 0.794
ASA score 0.957
   I 1 (3.8) 1 (4)
   II 11 (42.3) 11 (44)
   III 12 (46.2) 12 (48)
   IV 2 (7.7) 1 (4)
Obstruction 1 (3.8) 0 0.322
Neoadjuvant treatment 21 (80.8) 21 (84) 0.762
Adjuvant treatment 19 (73.1) 21 (84) 0.343
Anastomosis 1 (3.8) 20 (80) < 0.001a
T Stage 0.913
   pT3a,b 1 (3.8) 1 (4)
   pT3c,d 6 (23.1) 6 (24)
   pT4a 7 (26.9) 7 (28)
   pT4b 11 (42.3) 11 (44)
   pTx 1 (3.8) 0
Resection margins involved 5 (19) 7 (28) 0.426
Perforation 2 (7.7) 4 (16) 0.357
Transfusions 2.6 ± 2.4 1.12 ± 2.4 0.035a
Quality of the mesorectum[20-23] 0.351
   Good/Complete 16 (69.6) 13 (52)
   Partially good/Nearly complete 4 (17.4) 8 (32)
   Bad/Incomplete 3 (13) 4 (16)
aP: statistically significant. ASA: American Society of Anaesthesiologists.
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Figure 2  Overall disease-free survival after pelvic exenteration for locally 
advanced primary rectal cancer. 
0       10      20      30      40       50      60
t /mo
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
ul
at
iv
e 
su
rv
iv
al
Overall survival
Censored
Figure 3  Overall survival after pelvic exenteration for locally advanced 
primary rectal cancer.
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specimens from patients who underwent neoadjuvant 
treatment is matter of debate in the vast majority 
of cases, and the PelvEx collaborative found it to be 
significantly associated with survival[13]. The mean 
number of nodes isolated from the specimen was 
higher than 12, which is the minimum acceptable 
number for TME. However, in this series, the effect on 
oncologic outcome was less obvious when comparing 
pN+ and pN- patients. Given the importance of pT and 
pN status in colorectal cancer[34], this issue needs to 
be further investigated in LAPRC. We confirmed that R 
status was an independent predictor of LR, which was 
impaired by five-fold in the event of positive resection 
margins. Statistical significance was maintained even 
if we observed a wide CI; cautious interpretation is 
needed, but the clinical relevance is unquestioned. 
Kontovounisios et al[5] analysed the performance of 
dedicated PE MDT at a single unit, and they achieved 
an R0 rate of 93% by the last year of their report. 
Interestingly, there was an inverse relation between 
the number of referrals (increasing over time) and the 
relative number of procedures performed (decreasing). 
This outcome resulted from better patient selection and 
better surgical timing in the context of multidisciplinary 
treatment. Other series reported rates of R+ve 
resections similar to the one in our analysis[11,13]. 
OS after PE for LAPRC is intertwined with the 
radicality of resection and recurrence[8,13]. The largest 
international, prospective study on PE for LAPRC included 
1291 patients from 14 countries and showed a median 
5-year survival of 43 months. The rate of patients who 
were alive at 5-year follow up from our database was 
67.2%, which is at or above the upper limit of the ranges 
reported in the literature[6,12,26,30]. Reasons that could 
justify this finding include surgery probably not being 
offered to patients who might have been operated on 
in other centres with a more aggressive policy, e.g., 
patients with pelvic bone involvement. According to the 
beyond TME collaborative[19], only poor performance 
status/medically unfit patients, bilateral sciatic nerve 
involvement and circumferential bone involvement 
should be considered absolute contraindications to 
surgery. A more conservative approach in patients from 
the database appears to be a reasonable option. Another 
reason could be early referral to hospitals with dedicated 
units. Lastly, individual investigators might have decided 
not to include patients with more complex disease and 
predictable poorer outcomes.
The ideal management of patients with LAPRC arising 
in the lower rectum is still a matter of debate. Given 
the excellent results in terms of tumour clearance and 
quality of life achieved with TME, mutilating approaches 
such as PE are deemed overtreatment in many patients. 
However, this part of the rectum is associated with higher 
rates of complications, and optimizing the outcomes 
of surgery for LAPRC of the lower third is still matter of 
research[35,36]. After adjusting two groups of patients with 
a propensity-matched analysis, we observed a trend 
towards better specimen quality and increased LR-free 
intervals with similar OS. These findings need further 
evaluation and should be considered when planning 
future studies on PE or involving low rectal cancers.
Limitations
This study has several limitations, and our findings 
should be interpreted with caution. Voluntary inclusion 
of patients in registries might account for a selection 
bias, even if they are prospective. The analysis covered 
a 10-year timeframe and included patients operated on 
different centres. Multidisciplinary patient management 
is crucial in PE[5], and variability between hospitals could 
not be removed. However, there are no universally 
agreed-upon guidelines to indicate or contraindicate 
PE in LAPRC, despite the latest available beyond-TME 
Collaborative position paper, which advocated the need 
for further research on the topic as a matter of priority[19]. 
No validation of the data was planned. LR was dia-
gnosed by raising CEA associated with imaging proving 
recurrence, and this might have underestimated the 
actual incidence. Quality of life was not available in this 
study. Health-related quality of life and social function are 
of paramount importance in patients who are candidates 
for PE and should be considered an important endpoint 
of LARC surgery. The stressful experience that patients 
and families go through after receiving a diagnosis 
and when they are forced to face an advanced and 
aggressive disease is made even more difficult when 
the perspectives of the necessity of a definitive stoma 
(sometimes more than one) are considered. However, 
no dedicated questionnaires or assessments have been 
proposed and validated in this group of patients and 
should therefore be considered a research priority.
This study has strengths. Limited series of PE for 
LAPRC have been reported, and the findings described 
herein represent the second largest study with 5-year 
follow up available after the PelvEx Collaborative study. 
We suggested that patients with LAPRC of the lower third 
might benefit from a more aggressive surgical approach, 
and future studies could be designed to confirm the 
survival advantage in this group of patients. Some 
centres advocated PE in patients with liver metastases. 
The numbers were too small to conduct sub-analyses, 
and results could be misleading. Interestingly, distant 
metastases are usually a contraindication to PE in most 
referral centres[5]. As per the available position paper, 
LAPRC with metastases amenable to resection could 
benefit from PE, on the condition that a dedicated 
MDT agrees to the indication. In agreement with the 
statements of the beyond TME Collaborative[19], the 
outcomes of PE should be separately reported, and our 
manuscript only included this homogeneous group of 
patients.  
PE is an extensive procedure with significant rate of 
perioperative adverse events. The analysis of a national 
database on LAPRC treated with PE over 10 years 
confirmed the survival benefit of the procedure, which 
overwhelms the morbidity and mortality associated 
with it. The rates of LR, DFS and OS were in line with 
Pellino G et al . PE for LAPRC
5151 December 7, 2018|Volume 24|Issue 45|WJG|www.wjgnet.com
most of the reported studies, but any effort should be 
made to improve these results (e.g., via centralization, 
adherence to prospective registries and auditing, 
dedicated training). Disease-free resection margins (R0) 
comprise the aim of surgery, as they predict LR. PE 
should be carried out in dedicated units under the care 
of MDT to reduce or promptly treat complications, which 
impair long-term survival.
Compared with non-exenterative TME surgery, PE 
was associated with longer disease-free intervals and 
achieved similar OS in patients with LAPRC for low 
rectal cancer. 
Further studies are needed to clarify patient selection 
pathways and referral centre accreditation policies, and 
to assess quality of life after PE.
ARTICLE HIGHLIGHTS
Research background
Colorectal cancer is the fourth cause of death caused by cancer according to 
reports from the United States. Up to 33% of rectal cancers might present as 
locally advanced, requiring multidisciplinary approaches. Pelvic exenteration 
(PE) combined with multimodal treatment has resulted in increased survival in 
this population of patients, but there remains a need for further reports in the 
literature concerning the management of patients with primary locally advanced 
rectal cancer.
Research motivation
Previous studies suggested that an aggressive approach, with surgery 
combined with other treatment modalities, might confer good outcome in terms 
of tumour clearance and survival in locally advanced primary rectal cancer 
(LAPRC). Few reports have been published detailing the outcome of nationwide 
databases. 
Research objectives
This study aimed to investigate the outcome of PE for primary rectal cancer 
in patients included in the National Spanish Association of Surgeons Rectal 
Cancer Registry.
Research methods
This is a retrospective, observational study drafted according to the STROBE 
statement. Patients who underwent PE for LAPRC between 2006 and 2017 and 
who were registered in the Spanish Registry of Rectal Cancer of the Spanish 
Association of Surgeons were included if surgery was performed with curative 
intent and if 5-year follow up had been completed.
Short-term morbidity and mortality of the procedure and 5-year oncologic 
outcome represented the primary aims of this study. Secondary aims included a 
comparison of outcomes with a matched group of patients from the registry who 
underwent non-exenterative surgery for low rectal cancer during the same time 
frame.
Research results
PE were associated with perioperative mortality in approximately 2.5% of 
patients, and perioperative morbidity was common. More than 50% of patients 
had at least one complication, which required reoperation in 10%. Up to 10% of 
patients suffered from intra-abdominal septic complication. Wound-associated 
complications at the perineum were common, almost reaching 20%. The rate of 
resections with margins that involved tumours was 23%, and good quality of the 
mesorectum was achieved in 74% of specimens. 
Oncologic outcome was acceptable, with good life expectancy provided 
a free-free resection margin had been achieved. An involved margin was 
independently associated with increased risk of local recurrence [hazard 
ratio (HR) = 5.58, 95%CI: 1.04-30.07, P = 0.04]. Survival was impaired by 
perioperative complications [HR = 3.53, 95%CI: 1.12-10.94, P = 0.03].
In terms of comparison with non-exenterative procedures, the latter were 
associated with fewer blood transfusions (P = 0.035) and more anastomoses (P < 
0.001). However, resections with involved margins were less common after PE.
Research conclusions
PE is an extensive procedure with a significant rate of perioperative adverse 
events. However, our analysis of patients with LAPRC treated with this 
procedure over 10 years confirmed that the survival benefits justify an 
aggressive attitude, provided that oncologic clearance is achievable. These 
procedures must be performed in a dedicated unit, and patients be managed 
under the care of multidisciplinary teams. 
Research perspectives
An aggressive attitude could confer a significant survival gain in carefully 
selected patients with LAPRC. The use of national and International registries 
is of great value to monitor the performance of centres dealing with PE and 
internal auditing; therefore, their use should be encouraged.  
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